JP2021520825A - ガレクチン−１０抗体 - Google Patents

ガレクチン−１０抗体 Download PDF

Info

Publication number
JP2021520825A
JP2021520825A JP2020556304A JP2020556304A JP2021520825A JP 2021520825 A JP2021520825 A JP 2021520825A JP 2020556304 A JP2020556304 A JP 2020556304A JP 2020556304 A JP2020556304 A JP 2020556304A JP 2021520825 A JP2021520825 A JP 2021520825A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
galectin
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020556304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520825A5 (https=
JPWO2019197675A5 (https=
Inventor
ランブレヒト バート
ランブレヒト バート
サビデス サバス
サビデス サバス
ハマド ハミダ
ハマド ハミダ
ヴェルストラーテ ケネス
ヴェルストラーテ ケネス
ペルシエ ジャン‐ミッシェル
ペルシエ ジャン‐ミッシェル
ブランチェトト クリストプヘ
ブランチェトト クリストプヘ
サウンダース マイケル
サウンダース マイケル
デ ハード ハンス
デ ハード ハンス
ヴァン デル ウォニング バス
ヴァン デル ウォニング バス
ペルソン エマ
ペルソン エマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Original Assignee
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806099.6A external-priority patent/GB201806099D0/en
Priority claimed from GBGB1901648.4A external-priority patent/GB201901648D0/en
Application filed by Universiteit Gent filed Critical Universiteit Gent
Publication of JP2021520825A publication Critical patent/JP2021520825A/ja
Publication of JP2021520825A5 publication Critical patent/JP2021520825A5/ja
Publication of JPWO2019197675A5 publication Critical patent/JPWO2019197675A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020556304A 2018-04-13 2019-04-12 ガレクチン−１０抗体 Pending JP2021520825A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1806099.6A GB201806099D0 (en) 2018-04-13 2018-04-13 Galectin-10 Antibodies
GB1806099.6 2018-04-13
GBGB1901648.4A GB201901648D0 (en) 2019-02-06 2019-02-06 Galectin-10 antibodies
GB1901648.4 2019-02-06
PCT/EP2019/059570 WO2019197675A1 (en) 2018-04-13 2019-04-12 Galectin-10 antibodies

Publications (3)

Publication Number Publication Date
JP2021520825A true JP2021520825A (ja) 2021-08-26
JP2021520825A5 JP2021520825A5 (https=) 2022-04-20
JPWO2019197675A5 JPWO2019197675A5 (https=) 2022-04-20

Family

ID=66240109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020556304A Pending JP2021520825A (ja) 2018-04-13 2019-04-12 ガレクチン−１０抗体

Country Status (12)

Country Link
US (3) US11066473B2 (https=)
EP (1) EP3774905A1 (https=)
JP (1) JP2021520825A (https=)
KR (1) KR20210005070A (https=)
CN (1) CN112166126A (https=)
AU (1) AU2019250689A1 (https=)
BR (1) BR112020020868A2 (https=)
CA (1) CA3094215A1 (https=)
IL (1) IL278010A (https=)
MX (1) MX2020010821A (https=)
SG (1) SG11202009140SA (https=)
WO (1) WO2019197675A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023153496A1 (ja) * 2022-02-10 2023-08-17 国立大学法人大阪大学 好酸球増多症又は気管支喘息バイオマーカー

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
US11860114B2 (en) * 2020-03-26 2024-01-02 David Hurwitz Determining atomic coordinates from X-ray diffraction data
WO2021223079A1 (zh) * 2020-05-06 2021-11-11 科稷达隆(北京)生物技术有限公司 一种纳米抗体及其应用
CN113666999B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113667000B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 多肽在制备治疗2型免疫疾病的药物中的应用
CN113999287B (zh) * 2021-12-02 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
KR20240133723A (ko) 2022-01-18 2024-09-04 아르제넥스 비브이 Fab 단편의 분무화
WO2023150260A2 (en) * 2022-02-03 2023-08-10 Regents Of The University Of Minnesota Compounds that target tem8, compositions, and methods
CN115785245A (zh) * 2022-07-18 2023-03-14 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106645752A (zh) * 2016-12-27 2017-05-10 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE10333406A1 (de) * 2003-07-15 2005-02-10 Protagen Ag T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106645752A (zh) * 2016-12-27 2017-05-10 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEVEN J ACKERMAN; ET AL: "CHARCOT-LEYDEN CRYSTAL PROTEIN (GALECTIN-10) IS NOT A DUAL FUNCTION GALECTIN WITH 以下備考", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. VOL:277, NR:17,, JPN5021008431, 7 February 2002 (2002-02-07), US, pages 14859 - 14868, ISSN: 0005406424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023153496A1 (ja) * 2022-02-10 2023-08-17 国立大学法人大阪大学 好酸球増多症又は気管支喘息バイオマーカー

Also Published As

Publication number Publication date
SG11202009140SA (en) 2020-10-29
EP3774905A1 (en) 2021-02-17
WO2019197675A1 (en) 2019-10-17
CA3094215A1 (en) 2019-10-17
MX2020010821A (es) 2021-01-15
US11713354B2 (en) 2023-08-01
US20240026010A1 (en) 2024-01-25
CN112166126A (zh) 2021-01-01
US11066473B2 (en) 2021-07-20
KR20210005070A (ko) 2021-01-13
US20190367619A1 (en) 2019-12-05
BR112020020868A2 (pt) 2021-04-06
US20210332140A1 (en) 2021-10-28
AU2019250689A1 (en) 2020-10-08
IL278010A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US11713354B2 (en) Galectin-10 antibodies
TWI853077B (zh) 新型抗ｃｄ３９抗體
US9845363B2 (en) Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof
JP7444886B2 (ja) 補体関連疾患のための融合タンパク質構築物
US10183995B2 (en) IL-6 binding molecules
JP2017510575A (ja) 抗体−フィノマー複合体
TW201302794A (zh) 人類組織因子抗體及其用途
JP7610515B2 (ja) ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体
EP3381941A1 (en) Anti-epha4 antibody
CN106794129A (zh) 对il‑21具有特异性的结合分子及其用途
EP4331603A1 (en) Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
CN115697393A (zh) 抗PHF-tau抗体及其用途
KR20140009437A (ko) 항응고제 해독제
TW202444762A (zh) 自體免疫性疾病的治療
TW202136299A (zh) 雙特異性抗ｃｃｌ２抗體
US20250059285A1 (en) Galectin-10 antibodies
JP7839093B2 (ja) Ｋｌｋ５に対する抗体
HK40034251A (en) Galectin-10 antibodies
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
EA047651B1 (ru) Антитела против галектина-10
TW202523697A (zh) 抗ｔｓｌｐ抗體構築體及其用途
KR20260058849A (ko) 항-tslp 항체 작제물 및 이의 용도
WO2025260123A1 (en) Anti-c2 antibodies and uses thereof
BR122024025202A2 (pt) Anticorpos multiespecíficos, polinucleotídeo isolado, vetor de expressão, célula hospedeira, método para produzir anticorpos multiespecíficos, composição farmacêutica e uso
HK40110366A (zh) 半乳凝素-10抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220411

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250304